Andrographolide nanoparticles in leishmaniasis: Characterization and in vitro evaluations

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 1113-1121

  Roy, Partha ^a   Das, Suvadra ^a   Bera, Tanmoy ^b   Mondol, Subhasis ^b   Mukherjee, Arup ^a  

^a UNIVERSITY OF CALCUTTA   (India)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

Andrographolide; Antileishmanial chemotherapy; Nanoparticles

Indexed keywords

AMPHOTERICIN B; ANDROGRAPHOLIDE; NANOPARTICLE; POLYVINYL ALCOHOL; STABILIZING AGENT; STIBOGLUCONATE SODIUM; ANTIPROTOZOAL AGENT; DITERPENE;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROTOZOAL ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG SENSITIVITY; FEMALE; LEISHMANIASIS; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; TISSUE DISTRIBUTION; TROPICAL DISEASE; ZETA POTENTIAL; ANIMAL; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; HUMAN; INFRARED SPECTROSCOPY; LEISHMANIA DONOVANI; LIFE CYCLE; METABOLISM; PERITONEUM MACROPHAGE; SOLUBILITY; SURFACE PROPERTY; VISCERAL LEISHMANIASIS;

ANDROGRAPHIS PANICULATA;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; DITERPENES; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIFE CYCLE STAGES; MACROPHAGES, PERITONEAL; MICE; MICROSCOPY, ATOMIC FORCE; NANOPARTICLES; PARTICLE SIZE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES;

EID: 79954539322     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S14787     Document Type: Article

References (32)

1. Cavalli A, Bolognesi ML. Neglected tropical diseases: multitarget- directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J Med Chem. 2009;52(23): 7339-7359.
2. Connell DO. Neglected diseases. Nature. 2007;449(7159):157.
3. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat. 2004;7(4-5):257-266.
4. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003; 19(11):502-508.
5. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother. 2006;50(1):73-79.
6. Sinha J, Mukhopadhyay S, Das N, Basu MK. Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo. Drug Deliv. 2000;7(4):209-213.
7. Zhao D, Liao K, Ma X, Yan X. Study of the supramolecular inclusion of ß-cyclodextrin with andrographolide. J Incl Phenom Macrocycl Chem. 2002;43(3-4):259-264.
8. Zhu SP, Kang BA. Distribution and excretion of [35S] NaHSO3 - andrographolide by autoradiography. Acta Pharmacologica Sinica. 1981;2(4):266-269.
9. Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, Ravi Kumar MN. Sustained release nanoparticulate formulation containing antioxidantellagic acid as potential prophylaxis system for oral administration. J Drug Target. 2006;14(1):27-34.
10. Sarmento B, Ribeiro AJ, Veiga F, Ferreira DC, Neufeld RJ. Insulin- loaded nanoparticles are prepared by alginate ionotropic pregelation followed by chitosan polyelectrolyte complexation. J Nanosci Nanotechnol. 2007;7(8):1-9.
11. Chakraborty P, Das PK. Role of mannose/N-acetylglucosamine receptors in blood clearance and cellular attachment of Leishmania donovani. Mol Biochem Parasitol. 1988;28(1):55-62.
12. Ghosh AK, Bhattacharya FK, Ghosh DK. Leishmania donovani: amastigote inhibition and mode of action of berberine. Exp Parasitol. 1985;60(3):404-413.
13. Debrabant A, Joshi MB, Pimenta PF, Dwyer D. Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int J Parasitol. 2004;34(2):205-217.
14. Senero D, Lemesra JL. Axenically cultured amastigote forms as an in-vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother. 1997;41(5):972-976.
15. Callahan H, Kelley C, Peretra T, Grogle M. Microtubule inhibitors: structure-activity analysis suggest rational models to identify potentially active compounds. Antimicrob Agents Chemother. 1996;40(4): 947-952.
16. Chang K. Human cutaneous leishmaniasis in a mouse macrophage line: propagation and isolation of intracellular parasites. Science. 1980;209(4462):1240-1244.
17. Freitas MN, Marchetti JM. Nimesulide PLA microspheres as a potential sustained release system for the treatment of inflammatory diseases. Int J Pharm. 2005;295(1-2):201-211.
18. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: Systemic study of particle size and drug content. Int J Pharm. 2007;336(2):367-375.
19. Bellamy LJ. The Infrared Spectra of Complex Molecules. 2nd ed, Pt 1. New York: Chapman and Hall; 1980:30-56.
20. Mukherjee B, Santra K, Patttanaik G, Ghosh S. Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomed. 2008;3(4):487-496.
21. Korsemeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35.
22. Grattard N, Pernin M, Marty B, Roudaut G, Champion D, Meste ML. Study of release kinetics of small and high molecular weight substances dispersed into spray-dried ethylcellulose microspheres. J Control Rel. 2002;84(3):125-135.
23. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biol Dis. 2003;2(1):1-10.
24. Lala S, Pramanik S, Mukhopadhay S, Bandhopadhyay S, Basu MK. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target. 2004;12(3):165-175.
25. Cruz LJ, Luque-Ortega JR, Rivas L, Albericio F. Kahalalide F. An antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents. Mol Pharm. 2009;6(3):813-824.
26. Habtemariam S. In vitro antileishmanial effects of antibacterial diterpenes from two Ethiopian Premna species: P. schimperi and P. oligotricha. BMC Pharmacol. 2003;3(6):1-6.
27. Mishra SK, Sangwan NS, Sangwan RS. Andrographis paniculata (Kalmegh): A Review. Pharmacognosy Reviews. 2007;1(2):283-298.
28. Cava MP, Chan WR, Haynes LJ, Johnson LF, Weinstein B. The structure of andrographolide. Tetrahedron. 1962;18(4):397-403.
29. Lala S, Nandy AK, Mahato SB, Basu MK. Delivery in vivo of 14- deoxy-11-oxoandrographolide, an antileishmanial agent, by different drug carriers. Indian J Biochem Biophys. 2003;2:169-174.
30. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713-2722.
31. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in drug targeting: Opportunities and Challenges. Curr Nanosci. 2005;1(1):47-64.
32. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125(3):193-209.